4
MARKET OVERVIEW
Leukopaks propel CAR-T therapy advancements amid leukemia's rising clinical burden and donor challenges.
51
4.2.1.1
RISING UTILIZATION OF LEUKOPAKS IN CAR-T CELL THERAPY DEVELOPMENT
4.2.1.2
INCREASING INCIDENCE AND CLINICAL BURDEN OF LEUKEMIA
4.2.1.3
LEUKOPAKS AND LEUKAPHERESIS DRIVING ADVANCES IN RESEARCH & DEVELOPMENT ACTIVITIES
4.2.1.4
LEUKOPAKS AS KEY CONTRIBUTORS TO CAR-T CELL THERAPY CLINICAL TRIALS
4.2.2.1
ELEVATED COSTS OF THERAPEUTIC LEUKAPHERESIS AND LEUKOPAK PRODUCTS
4.2.2.2
LIMITED DONOR AVAILABILITY AND STRINGENT SCREENING CRITERIA FOR LEUKAPHERESIS
4.2.2.3
SHORTAGE OF SKILLED HEALTHCARE PROFESSIONALS IN APHERESIS AND CELL THERAPY PROCEDURES
4.2.2.4
COMPLICATIONS ASSOCIATED WITH THERAPEUTIC LEUKAPHERESIS
4.2.3.1
INCREASING FOCUS ON LEUKAPHERESIS IN PEDIATRIC PATIENTS
4.2.3.2
RISE IN INVESTMENTS IN CAR-T THERAPIES IN EMERGING ECONOMIES
4.2.3.3
GAPS IN CURRENT LEUKAPHERESIS TECHNOLOGIES
4.2.4.1
INFECTIOUS DISEASE RISKS RELATED TO SAFETY OF BLOOD TRANSFUSION IN EMERGING ECONOMIES
4.2.4.2
DONOR VARIABILITY AND INCONSISTENT LEUKOPAK QUALITY
4.3
UNMET NEEDS & WHITE SPACES
4.3.1
UNMET NEEDS IN LEUKAPHERESIS MARKET
4.3.2
WHITE SPACE OPPORTUNITIES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1
INTERCONNECTED MARKETS
4.4.2
CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
4.5.1
STRATEGIC MOVES BY TIER 1/2/3 PLAYERS IN LEUKAPHERESIS MARKET
5
INDUSTRY TRENDS
Navigate competitive pressures and leverage pricing trends to capitalize on leukapheresis market opportunities.
65
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
THREAT OF NEW ENTRANTS
5.1.2
THREAT OF SUBSTITUTES
5.1.3
BARGAINING POWER OF SUPPLIERS
5.1.4
BARGAINING POWER OF BUYERS
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS & FORECAST
5.2.3
TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4
TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY
5.3
SUPPLY CHAIN ANALYSIS
5.5.1
LEUKAPHERESIS MARKET PROVIDERS
5.6
PRICING ANALYSIS (LEUKOPAKS MARKET)
5.6.1
AVERAGE SELLING PRICE TREND FOR NON-MOBILIZED LEUKOPAKS, BY REGION, 2023–2025 (USD)
5.6.2
AVERAGE SELLING PRICE TREND FOR MOBILIZED LEUKOPAKS, BY REGION, 2023–2025 (USD)
5.7.1
IMPORT DATA FOR HS CODE 901890
5.7.2
EXPORT DATA FOR HS CODE 901890
5.8
REIMBURSEMENT SCENARIO
5.9
KEY CONFERENCES & EVENTS (2026–2027)
5.10
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.11
INVESTMENT & FUNDING SCENARIO
5.13
IMPACT OF 2025 US TARIFF ON LEUKAPHERESIS MARKET
5.13.3
PRICE IMPACT ANALYSIS
5.13.5
IMPACT ON END-USE SEGMENTS
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVE IMPACT, PATENTS, AND INNOVATIONS
AI-driven innovations revolutionize leukapheresis, enhancing efficiency, compliance, and market potential.
93
6.1.1
KEY EMERGING TECHNOLOGIES
6.1.1.1
AUTOMATED & AI-ENABLED APHERESIS SYSTEMS
6.1.1.2
CLOSED-LOOP & GMP-COMPLIANT PROCESSING SYSTEMS
6.1.1.3
CRYOPRESERVATION & CRYO-PROCESSED LEUKOPAKS TECHNOLOGIES
6.1.2
COMPLEMENTARY TECHNOLOGIES
6.1.2.1
CELL PROCESSING & MANUFACTURING PLATFORMS (CGT ECOSYSTEM)
6.1.2.2
DIGITAL MONITORING, DATA INTEGRATION, AND WORKFLOW SOFTWARE
6.1.3
ADJACENT TECHNOLOGIES
6.1.3.1
REGENERATIVE MEDICINE & STEM CELL TECHNOLOGIES
6.2
TECHNOLOGY/PRODUCT ROADMAP
6.2.1
NEAR TERM (2025–2027)
6.2.2
MID TERM (2028–2030)
6.3.1
JURISDICTION AND TOP APPLICANT ANALYSIS
6.4.1
CELL & GENE THERAPY (CAR-T, TCR, NK CELLS)
6.4.2
DECENTRALIZED & POINT-OF-CARE CELL COLLECTION
6.4.3
STEM CELL TRANSPLANTATION & REGENERATIVE MEDICINE
6.5
IMPACT OF AI/GEN AI ON LEUKAPHERESIS MARKET
6.5.2
MARKET POTENTIAL OF AI IN LEUKAPHERESIS
6.5.4
KEY COMPANIES IMPLEMENTING AI
7
SUSTAINABILITY & REGULATORY BEHAVIOR
Navigate global sustainability regulations with insights into regional frameworks and eco-friendly initiatives.
103
7.1.1
REGULATORY FRAMEWORK
7.1.1.5
MIDDLE EAST & AFRICA
7.1.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
SUSTAINABILITY INITIATIVES
7.2.1
RECYCLED AND ECO-FRIENDLY MATERIALS FOR LEUKAPHERESIS
7.2.2
SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.2.3
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Unlock stakeholder influence and unmet needs to drive profitable buying decisions in leukopaks.
110
8.1
KEY STAKEHOLDERS & BUYING CRITERIA
8.1.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.2
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.2.1
DECISION-MAKING PROCESS
8.2.2
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.2.3
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.2.4
MARKET PROFITABILITY
9
LEUKAPHERESIS MARKET, BY PRODUCT TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million and Units | 14 Data Tables
115
9.2.1
SINGLE-USE, PROCEDURE-DRIVEN CONSUMPTION TO BOOST SEGMENT
9.2.2
TUBING SETS & COLLECTION BAGS
9.2.2.1
RISING LEUKAPHERESIS PROCEDURE VOLUMES DRIVING DEMAND FOR TUBING SETS & COLLECTION BAGS
9.2.3
FILTERS & MEMBRANE CONSUMABLES
9.2.3.1
GROWING ADOPTION OF LEUKOCYTE REMOVAL FILTERS IN INFLAMMATORY DISEASE MANAGEMENT
9.2.4
COLLECTION KITS & ACCESSORIES
9.2.4.1
INCREASING LEUKAPHERESIS AND LEUKOPAK COLLECTION ACTIVITIES DRIVING DEMAND FOR COLLECTION KITS AND ACCESSORIES
9.3.1
CENTRIFUGAL DEVICES
9.3.1.1
INCREASING INSTALLATION IN HOSPITALS TO DRIVE MARKET
9.3.1.2
GLOBAL VOLUME ANALYSIS: CENTRIFUGAL DEVICES MARKET (2024–2031)
9.3.2
MEMBRANE SEPARATORS
9.3.2.1
DIFFICULTY IN SEPARATING LARGE VOLUMES OF PLASMA TO LIMIT MARKET
10
LEUKAPHERESIS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 4 Data Tables
129
10.2
RESEARCH APPLICATIONS
10.2.1
EXPANDING CELL & GENE THERAPY PIPELINE TO DRIVE THE SEGMENT
10.3
THERAPEUTIC APPLICATIONS
10.3.1
INCREASING ADOPTION OF LEUKAPHERESIS IN LEUKEMIA MANAGEMENT DRIVING MARKET GROWTH
11
LEUKAPHERESIS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 6 Data Tables
134
11.2
BLOOD COMPONENT PROVIDERS & BLOOD CENTERS
11.2.1
RISING BLOOD DONATION AND TRANSFUSION NEEDS DRIVING LEUKAPHERESIS DEMAND
11.3
HOSPITALS & TRANSFUSION CENTERS
11.3.1
HIGH PROCEDURAL VOLUMES IN HOSPITALS TO DRIVE LEUKAPHERESIS DEMAND
11.4
ACADEMIC & RESEARCH INSTITUTES
11.4.1
INCREASING ACADEMIC–INDUSTRY COLLABORATIONS TO BOOST MARKET
11.5
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.5.1
GROWING NUMBER OF CLINICAL TRIALS TO BOOST SEGMENT
12
LEUKOPAKS MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 15 Data Tables
143
12.2.1
INCREASING USE OF MOBILIZED LEUKOPAKS IN CLINICAL RESEARCH TO DRIVE MARKET
12.2.2
GLOBAL VOLUME ANALYSIS: MOBILIZED LEUKOPAKS MARKET (2024–2031)
12.3
NON-MOBILIZED LEUKOPAKS
12.3.1
ADOPTION OF NON-MOBILIZED LEUKOPAKS DRIVEN BY LOWER COST AND CELL YIELD
12.3.2
GLOBAL VOLUME ANALYSIS: NON-MOBILIZED LEUKOPAKS MARKET (2024–2031)
12.4.1
INCREASING DEMAND FOR DISEASE-STATE LEUKOPAKS IN ADVANCED THERAPEUTIC RESEARCH DRIVING MARKET GROWTH”
12.4.2
GLOBAL VOLUME ANALYSIS: DISEASED LEUKOPAKS MARKET (2024–2031)
12.5.1
INCREASING RESEARCH FOCUS ON CELL-BASED THERAPIES TO FUEL MARKET
12.5.2
GLOBAL VOLUME ANALYSIS: ISOLATED PBMCS MARKET (2024–2031)
13
LEUKOPAKS MARKET, BY INDICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 8 Data Tables
157
13.2
ACUTE LYMPHOCYTIC LEUKEMIA
13.2.1
INCREASING INCIDENCE OF ACUTE LYMPHOCYTIC LEUKEMIA SUPPORTING MARKET GROWTH
13.3.1
RISING MULTIPLE MYELOMA CASES DRIVING MARKET EXPANSION
13.4
NON-HODGKIN’S LYMPHOMA
13.4.1
DEVELOPMENT OF NOVEL THERAPIES TO BOOST MARKET
13.5
CHRONIC LYMPHOCYTIC LEUKEMIA
13.5.1
GROWING PREVALENCE OF CHRONIC LYMPHOCYTIC LEUKEMIA DRIVING SEGMENT EXPANSION
13.6.1
DEVELOPMENT OF NEW DIAGNOSTIC TECHNIQUES TO DRIVE SEGMENT
13.7
HEPATOCELLULAR CARCINOMA
13.7.1
INCREASING INCIDENCE OF VIRAL HEPATITIS TO FUEL SEGMENT
14
LEUKOPAKS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 4 Data Tables
170
14.2
ACADEMIC & RESEARCH INSTITUTES
14.2.1
INCREASING INDUSTRY–ACADEMIC COLLABORATIONS DRIVING MARKET GROWTH
14.3
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.3.1
RISING DEMAND FOR TARGETED CELL-BASED DRUG DEVELOPMENT DRIVING LEUKOPAK ADOPTION
14.4
CONTRACT RESEARCH ORGANIZATIONS
14.4.1
INCREASING CRO-LED CLINICAL ACTIVITIES DRIVING DEMAND FOR LEUKAPHERESIS-DERIVED MATERIALS
15
LEUKAPHERESIS MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 20 Countries | 207 Data Tables.
177
15.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
15.2.2
NORTH AMERICA VOLUME ANALYSIS: LEUKOPAKS TYPE (2024–2031)
15.2.3.1
STRONG PRESENCE OF BIOPHARMACEUTICAL LEADERS AND EXPANDING CELL THERAPY ECOSYSTEM DRIVING MARKET GROWTH
15.2.4.1
INCREASING LEUKEMIA INCIDENCE AND ADVANCEMENTS IN CAR-T THERAPIES SUPPORTING MARKET GROWTH IN CANADA
15.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
15.3.2
EUROPE VOLUME ANALYSIS: LEUKOPAKS TYPE (2024–2031)
15.3.3.1
RISING HEALTHCARE EXPENDITURE, EXPANDING ACADEMIC–CLINICAL CELL THERAPY ECOSYSTEM TO DRIVE MARKET GROWTH
15.3.4.1
EXPANDING APHERESIS CAPACITY AND CAR-T THERAPIES ADOPTION TO SUPPORT MARKET GROWTH
15.3.1.1
CENTRALIZED CAR-T DELIVERY SYSTEM AND STRONG PUBLIC REIMBURSEMENT TO PROPEL MARKET GROWTH
15.3.2.1
RISING ELDERLY PATIENT POOL AND HIGH CANCER INCIDENCE TO DRIVE MARKET GROWTH
15.3.3.1
RISING HEMATOLOGIC CANCER BURDEN TO SUPPORT MARKET GROWTH
15.3.4.1
STRONG CLINICAL RESEARCH ECOSYSTEM AND STRUCTURED REIMBURSEMENT FRAMEWORK TO BOOST THE MARKET
15.3.5.1
STRONG HEALTHCARE INFRASTRUCTURE AND AGING POPULATION TO DRIVE MARKET
15.3.6.1
RISE IN CANCER INCIDENCE TO BOOST THE MARKET
15.3.7.1
EARLY ADOPTION OF CELL THERAPIES TO DRIVE MARKET DEMAND
15.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
15.4.2
ASIA PACIFIC VOLUME ANALYSIS: LEUKOPAKS TYPE (2024–2031)
15.4.3.1
INCREASING HEMATOLOGIC CANCER BURDEN, CAR-T EXPANSION, AND BIOTECH INVESTMENTS DRIVING LEUKAPHERESIS GROWTH IN CHINA
15.4.4.1
MODERATE-TO-HIGH HEALTHCARE EXPENDITURE SUPPORTING LEUKAPHERESIS MARKET GROWTH
15.4.5.1
RISING GOVERNMENT INVESTMENT IN HEALTHCARE TO DRIVE MARKET GROWTH
15.4.6.1
CLINICAL INTEGRATION OF CAR-T THERAPIES IN HOSPITALS AS CORE GROWTH DRIVER FOR LEUKAPHERESIS IN AUSTRALIA
15.4.7.1
INTEGRATION OF DIGITAL AND AUTOMATED CELL PROCESSING TECHNOLOGIES DRIVING GROWTH IN THE LEUKAPHERESIS MARKET
15.4.8.1
STRENGTHENING THERAPEUTIC APHERESIS INFRASTRUCTURE AS A CORE GROWTH DRIVER FOR THE NEW ZEALAND LEUKAPHERESIS MARKET
15.4.9.1
RISING ONCOLOGY DEMAND FOR CELL-BASED THERAPIES DRIVING LEUKAPHERESIS MARKET GROWTH
15.4.10
REST OF ASIA PACIFIC
15.5.1
LATIN AMERICA VOLUME ANALYSIS: LEUKOPAKS TYPE (2024–2031)
15.5.2.1
ROLE OF BLOOD DONATION, TRANSPLANT ACTIVITY, AND CELL THERAPY EXPANSION IN DRIVING THE LEUKAPHERESIS AND LEUKOPAK MARKET
15.5.3.1
EMERGING CAR-T THERAPY AND COST-DRIVEN LEUKEMIA CARE MARKET IN MEXICO
15.5.4
REST OF LATIN AMERICA
15.6
MIDDLE EAST & AFRICA
15.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
15.6.2
MIDDLE EAST & AFRICA VOLUME ANALYSIS: LEUKOPAKS TYPE (2024–2031)
15.6.3.1
KINGDOM OF SAUDI ARABIA (KSA)
15.6.3.1.1
TRANSFORMING CLINICAL RESEARCH IN SAUDI ARABIA THROUGH HEALTHCARE INNOVATION INITIATIVES
15.6.3.2
UNITED ARAB EMIRATES (UAE)
15.6.3.2.1
EMERGENCE AS A REGIONAL HUB FOR ADVANCED PRECISION MEDICINE
15.6.3.3
OTHER GCC COUNTRIES
15.6.4
REST OF MIDDLE EAST & AFRICA
16
COMPETITIVE LANDSCAPE
Discover key strategies and market positions shaping the leukapheresis competitive landscape.
285
16.2
KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2022–2026
16.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN LEUKAPHERESIS MARKET
16.3
REVENUE ANALYSIS, 2023–2025
16.3.1
LEUKAPHERESIS MARKET: REVENUE ANALYSIS
16.3.2
LEUKOPAKS MARKET: REVENUE ANALYSIS
16.4
MARKET SHARE ANALYSIS, 2025
16.4.1
LEUKAPHERESIS MARKET: SHARE ANALYSIS
16.4.2
LEUKOPAKS MARKET: SHARE ANALYSIS
16.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
16.5.1.2
EMERGING LEADERS
16.5.1.3
PERVASIVE PLAYERS
16.5.1.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
16.5.1.5.1
COMPANY FOOTPRINT
16.5.1.5.2
BY REGION FOOTPRINT
16.5.1.5.3
BY PRODUCT TYPE FOOTPRINT
16.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
16.6.1.1
PROGRESSIVE COMPANIES
16.6.1.2
RESPONSIVE COMPANIES
16.6.1.3
DYNAMIC COMPANIES
16.6.1.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
16.6.1.5.1
DETAILED LIST OF KEY STARTUPS/SMES
16.6.1.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
16.7
COMPANY VALUATION AND FINANCIAL METRICS
16.7.1
FINANCIAL METRICS: LEUKAPHERESIS MARKET
16.7.2
COMPANY VALUATION : LEUKAPHERESIS MARKET
16.7.3
FINANCIAL METRICS: LEUKOPAKS MARKET
16.7.4
COMPANY VALUATION: LEUKOPAKS MARKET
16.8
LEUKOPAKS BRAND/PRODUCT COMPARISON
16.9
LEUKAPHEREIS BRAND/PRODUCT COMPARISON
16.10
COMPETITIVE SCENARIO
16.10.1
LEUKAPHERESIS MARKET
16.10.1.1
PRODUCT LAUNCHES & APPROVALS
16.10.2.1
PRODUCT LAUNCHES & APPROVALS
17
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
311
17.1
LEUKAPHERESIS PRODUCTS MARKET: KEY PLAYERS
17.1.1
TERUMO CORPORATION
17.1.1.1
BUSINESS OVERVIEW
17.1.1.2
PRODUCTS OFFERED
17.1.1.3
RECENT DEVELOPMENTS
17.1.1.3.1
PRODUCT LAUNCHES & APPROVALS
17.1.1.4.2
STRATEGIC CHOICES
17.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
17.1.2
FRESENIUS SE & CO. KGAA
17.1.3
HAEMONETICS CORPORATION
17.1.5
SUMITOMO BAKELITE CO., LTD.
17.1.6
DANAHER CORPORATION
17.1.7
OTSUKA HOLDINGS CO., LTD.
17.1.8
ASAHI KASEI MEDICAL CO., LTD.
17.2
LEUKAPHERESIS PRODUCTS MARKET: OTHER PLAYERS
17.2.3
GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.
17.2.4
SAFETRAN BIOMEDICAL INC.
17.2.5
MITRA INDUSTRIES PRIVATE LIMITED
17.3
LEUKOPAKS MARKET: KEY PLAYERS
17.3.3
CHARLES RIVER LABORATORIES
17.3.4
CELLEX CELL PROFESSIONALS
17.3.5
STEMCELL TECHNOLOGIES
17.3.7
DISCOVERY LIFE SCIENCES
17.3.11
SANGUINE BIOSCIENCES
17.4
LEUKOPAKS MARKET: OTHER PLAYERS
17.4.4
FIRST CHOICE BIO INC.
18
RESEARCH METHODOLOGY
386
18.1.1.1
KEY DATA FROM SECONDARY SOURCES
18.2
MARKET SIZE ESTIMATION: LEUKAPHERESIS MARKET
18.3
MARKET GROWTH RATE PROJECTIONS
18.5
RESEARCH ASSUMPTIONS
18.5.1
GROWTH RATE ASSUMPTIONS
18.7.1
METHODOLOGY-RELATED LIMITATIONS
18.7.2
SCOPE-RELATED LIMITATIONS
18.8
RESEARCH LIMITATIONS
19.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3
CUSTOMIZATION OPTIONS
19.3.1
COMPANY INFORMATION
19.3.2
GEOGRAPHIC ANALYSIS
19.3.3
REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
19.3.4
COUNTRY-LEVEL VOLUME ANALYSIS
19.3.5
ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
TABLE 1
LEUKAPHERESIS MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2
EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
TABLE 3
COST OF LEUKOPAKS, BY TYPE
TABLE 4
DONOR SELECTION CRITERIA
TABLE 5
FREQUENCY OF BLOOD DONATION FROM HEALTHY DONORS
TABLE 6
LEUKAPHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 7
GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION)
TABLE 8
LIST OF KEY LEUKAPHERESIS DEVICES + DISPOSABLES MANUFACTURERS
TABLE 9
LIST OF KEY LEUKOPAKS MANUFACTURERS
TABLE 10
LIST OF KEY END USERS
TABLE 11
LIST OF KEY REGULATORY BODIES
TABLE 12
AVERAGE SELLING PRICE OF NON-MOBILIZED LEUKOPAKS, 2025 (USD)
TABLE 13
AVERAGE SELLING PRICE OF MOBILIZED LEUKOPAKS, 2025 (USD)
TABLE 14
AVERAGE SELLING PRICE OF DISEASED LEUKOPAKS, 2025 (USD)
TABLE 15
AVERAGE SELLING PRICE OF ISOLATED PBMCS, 2025 (USD)
TABLE 16
IMPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 17
EXPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 18
LEUKAPHERESIS MARKET: MAJOR CONFERENCES & EVENTS IN 2026–2027
TABLE 19
CASE STUDY 1: RAPID CYTOREDUCTION IN PEDIATRIC ACUTE LEUKEMIA USING LEUKAPHERESIS
TABLE 20
CASE STUDY 2: GLOBAL CELL THERAPY TRIAL ENABLED BY LEUKAPHERESIS INTEGRATION
TABLE 21
CASE STUDY 3: THERAPEUTIC LEUKAPHERESIS IN SEVERE PNEUMONIA WITH HYPERLEUKOCYTOSIS
TABLE 22
US-ADJUSTED RECIPROCAL TARIFF RATES, 2024
TABLE 23
KEY PRODUCT-RELATED TARIFF EFFECTIVE
TABLE 24
NORTH AMERICA: IMPACT OF US TARIFFS
TABLE 25
ASIA PACIFIC: IMPACT OF US TARIFFS
TABLE 26
EUROPE: IMPACT OF US TARIFFS
TABLE 27
LATIN AMERICA: IMPACT OF US TARIFFS
TABLE 28
LEUKAPHERESIS MARKET: KEY PATENTS, 2023–2025
TABLE 29
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 30
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 31
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 32
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 33
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 34
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LEUKOPAKS
TABLE 35
KEY BUYING CRITERIA FOR LEUKOPAKS, BY TYPE
TABLE 36
LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 37
DISPOSABLES: LEUKAPHERESIS MARKET, BY PRODUCT TYPE 2024–2031 (USD MILLION)
TABLE 38
LEUKAPHERESIS DISPOSABLE PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39
TUBING SETS & COLLECTION BAGS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 40
COMMERCIALLY AVAILABLE FILTERS & MEMBRANE CONSUMABLES
TABLE 41
FILTERS & MEMBRANE CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 42
COMMERCIALLY AVAILABLE COLLECTION KITS & ACCESSORIES
TABLE 43
COLLECTION KITS & ACCESSORIES MARKET, BY TYPE,2024–2031 (USD MILLION)
TABLE 44
LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 45
CENTRIFUGAL DEVICES AVAILABLE
TABLE 46
CENTRIFUGAL DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47
CENTRIFUGAL DEVICES VOLUME MARKET, 2024–2031 (UNITS SOLD)
TABLE 48
MEMBRANE SEPARATORS AVAILABLE
TABLE 49
MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50
LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 51
COMPANIES DEVELOPING FDA-APPROVED CAR-T CELL THERAPIES
TABLE 52
LEUKAPHERESIS MARKET IN RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53
LEUKAPHERESIS MARKET IN THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54
LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 55
LEUKAPHERESIS MARKET FOR BLOOD COMPONENT PROVIDERS & BLOOD CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56
LEUKAPHERESIS MARKET FOR HOSPITALS & TRANSFUSION CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57
LEUKAPHERESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58
CAR-T CELL THERAPY UNDER CLINICAL TRIALS
TABLE 59
LEUKAPHERESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60
LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 61
LEUKOPAKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62
MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63
MOBILIZED LEUKOPAKS MARKET VOLUME, BY REGION, 2024–2031 (NO. OF BAGS)
TABLE 64
NUMBER OF CELLS IN NON-MOBILIZED LEUKOPAKS
TABLE 65
COMPARATIVE ANALYSIS OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS
TABLE 66
COMPOSITION OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS
TABLE 67
NON-MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68
NON-MOBILIZED LEUKOPAKS MARKET VOLUME, BY REGION, 2024–2031 (NO. OF BAGS)
TABLE 69
DISEASED CELL LEUKOPAKS AND THEIR ROLE IN CELL THERAPY
TABLE 70
DISEASED LEUKOPAKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71
DISEASED LEUKOPAKS MARKET VOLUME, BY REGION, 2024–2031 (NO. OF BAGS)
TABLE 72
IMMUNE CELL TYPES AND TARGETED DISEASES
TABLE 73
ISOLATED PBMCS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74
ISOLATED PBMCS MARKET VOLUME, BY REGION, 2024–2031 (NO. OF BAGS)
TABLE 75
LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 76
LEUKOPAKS MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77
LEUKOPAKS MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78
LEUKOPAKS MARKET FOR NON-HODGKIN’S LYMPHOMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79
LEUKOPAKS MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80
LEUKOPAKS MARKET FOR PANCREATIC CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81
LEUKOPAKS MARKET FOR HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82
LEUKOPAKS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83
LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 84
LEUKOPAKS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85
LEUKOPAKS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86
LEUKOPAKS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87
LEUKAPHERESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 88
LEUKOPAKS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 89
MAJOR LEUKAPHERESIS MARKET PLAYERS IN NORTH AMERICA
TABLE 90
NORTH AMERICA: LEUKAPHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91
NORTH AMERICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 92
NORTH AMERICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 93
NORTH AMERICA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 94
NORTH AMERICA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 95
NORTH AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 96
NORTH AMERICA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 97
US: KEY MACROINDICATORS
TABLE 98
US: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 99
US: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 100
US: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 101
US: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 102
US: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 103
US: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 104
CANADA: KEY MACROINDICATORS
TABLE 105
CANADA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 106
CANADA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 107
CANADA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 108
CANADA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 109
CANADA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 110
CANADA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 111
EUROPE: LEUKOPAKS MARKET, BY LEUKOPAK TYPE, 2024–2031 (MILLION UNIT BAGS)
TABLE 112
EUROPE: LEUKAPHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113
EUROPE: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 114
EUROPE: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 115
EUROPE: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 116
EUROPE: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 117
EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 118
EUROPE: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 119
GERMANY: KEY MACROINDICATORS
TABLE 120
GERMANY: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 121
GERMANY: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 122
GERMANY: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 123
GERMANY: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 124
GERMANY: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 125
GERMANY: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 126
UK: KEY MACROINDICATORS
TABLE 127
UK: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 128
UK: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 129
UK: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 130
UK: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 131
UK: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 132
UK: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 133
FRANCE: KEY MACROINDICATORS
TABLE 134
SPAIN: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 135
SPAIN: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 136
SPAIN: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 137
SPAIN: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 138
ITALY: KEY MACROINDICATORS
TABLE 139
ITALY: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 140
ITALY: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 141
ITALY: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 142
ITALY: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 143
ITALY: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 144
ITALY: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 145
SPAIN: KEY MACROINDICATORS
TABLE 146
NETHERLANDS: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 147
NETHERLANDS: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 148
NETHERLANDS: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 149
NETHERLANDS: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 150
NETHERLANDS: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 151
NETHERLANDS: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 152
POLAND: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 153
POLAND: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 154
POLAND: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 155
POLAND: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 156
POLAND: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 157
POLAND: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 158
SWITZERLAND: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 159
SWITZERLAND: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 160
SWITZERLAND: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 161
SWITZERLAND: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 162
SWITZERLAND: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 163
SWITZERLAND: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 164
REST OF EUROPE: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 165
REST OF EUROPE: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 166
REST OF EUROPE: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 167
REST OF EUROPE: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 168
REST OF EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 169
REST OF EUROPE: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 170
ASIA PACIFIC: LEUKAPHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 171
ASIA PACIFIC: LEUKOPAK PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172
ASIA PACIFIC: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 173
ASIA PACIFIC: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 174
ASIA PACIFIC: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 175
ASIA PACIFIC: LEUKOPAKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176
ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 177
ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 178
ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 179
ASIA PACIFIC: LEUKOPAKS MARKET, BY LEUKOPAK TYPE, 2024–2031 (MILLION UNIT BAGS)
TABLE 180
CHINA: KEY MACROINDICATORS
TABLE 181
CHINA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 182
CHINA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 183
CHINA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 184
CHINA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 185
CHINA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 186
CHINA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 187
JAPAN: KEY MACROINDICATORS
TABLE 188
JAPAN: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 189
JAPAN: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 190
JAPAN: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 191
JAPAN: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 192
JAPAN: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 193
JAPAN: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 194
INDIA: KEY MACROINDICATORS
TABLE 195
INDIA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 196
INDIA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 197
INDIA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 198
INDIA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 199
INDIA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 200
INDIA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 201
AUSTRALIA: KEY MACROINDICATORS
TABLE 202
AUSTRALIA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 203
AUSTRALIA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 204
AUSTRALIA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 205
AUSTRALIA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 206
AUSTRALIA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 207
AUSTRALIA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 208
SOUTH KOREA: KEY MACROINDICATORS
TABLE 209
SOUTH KOREA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 210
SOUTH KOREA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 211
SOUTH KOREA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 212
SOUTH KOREA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 213
SOUTH KOREA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 214
SOUTH KOREA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 215
NEW ZEALAND: KEY MACROINDICATORS
TABLE 216
NEW ZEALAND: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 217
NEW ZEALAND: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 218
NEW ZEALAND: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 219
NEW ZEALAND: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 220
NEW ZEALAND: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 221
NEW ZEALAND: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 222
THAILAND: KEY MACROINDICATORS
TABLE 223
THAILAND: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 224
THAILAND: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 225
THAILAND: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 226
THAILAND: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 227
THAILAND: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 228
THAILAND: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 229
ROAPAC: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 230
ROAPAC: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 231
ROAPAC: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 232
ROAPAC: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 233
ROAPAC: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 234
ROAPAC: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 235
LATIN AMERICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 236
LATIN AMERICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 237
LATIN AMERICA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 238
LATIN AMERICA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 239
LATIN AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 240
LATIN AMERICA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 241
BRAZIL: KEY MACROINDICATORS
TABLE 242
BRAZIL: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 243
BRAZIL: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 244
BRAZIL: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 245
BRAZIL: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 246
BRAZIL: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 247
BRAZIL: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 248
MEXICO: KEY MACROINDICATORS
TABLE 249
MEXICO: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 250
MEXICO: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 251
MEXICO: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 252
MEXICO: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 253
MEXICO: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 254
MEXICO: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 255
REST OF LATIN AMERICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 256
REST OF LATIN AMERICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 257
REST OF LATIN AMERICA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 258
REST OF LATIN AMERICA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 259
REST OF LATIN AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 260
REST OF LATIN AMERICA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 261
MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 262
MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 263
MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 264
MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 265
MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 266
MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 267
MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY LEUKOPAK TYPE, 2024–2031 (MILLION UNIT BAGS)
TABLE 268
KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS
TABLE 269
KINGDOM OF SAUDI ARABIA (KSA): LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 270
KINGDOM OF SAUDI ARABIA (KSA): LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 271
KINGDOM OF SAUDI ARABIA (KSA): LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 272
KINGDOM OF SAUDI ARABIA (KSA): LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 273
KINGDOM OF SAUDI ARABIA (KSA): LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 274
KINGDOM OF SAUDI ARABIA (KSA): LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 275
UNITED ARAB EMIRATES (UAE): KEY MACROINDICATORS
TABLE 276
UNITED ARAB EMIRATES (UAE): LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 277
UNITED ARAB EMIRATES (UAE): LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 278
UNITED ARAB EMIRATES (UAE): LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 279
UNITED ARAB EMIRATES (UAE): LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 280
UNITED ARAB EMIRATES (UAE): LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 281
UNITED ARAB EMIRATES (UAE): LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 282
OTHER GCC COUNTRIES: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 283
OTHER GCC COUNTRIES: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 284
OTHER GCC COUNTRIES: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 285
OTHER GCC COUNTRIES: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 286
OTHER GCC COUNTRIES: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 287
OTHER GCC COUNTRIES: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 288
REST OF MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 289
REST OF MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 290
REST OF MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 291
REST OF MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 292
REST OF MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 293
REST OF MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 294
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN LEUKAPHERESIS MARKET, JANUARY 2023–MARCH 2026
TABLE 295
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN LEUKOPAKS MARKET, JANUARY 2023–MARCH 2026
TABLE 296
LEUKAPHERESIS MARKET: DEGREE OF COMPETITION
TABLE 297
LEUKOPAKS MARKET: DEGREE OF COMPETITION
TABLE 298
LEUKOPAKS MARKET: REGION FOOTPRINT
TABLE 299
LEUKOPAKS MARKET: BY PRODUCT TYPE FOOTPRINT
TABLE 300
LEUKOPAKS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 301
LEUKOPAKS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS
TABLE 302
LEUKAPHERESIS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026
TABLE 303
LEUKAPHERESIS MARKET: DEALS, JANUARY 2023–MARCH 2026
TABLE 304
LEUKAPHERESIS MARKET: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 305
LEUKOPAKS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026
TABLE 306
LEUKOPAKS MARKET: DEALS, JANUARY 2023–MARCH 2026
TABLE 307
LEUKOPAKS MARKET: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 308
TERUMO CORPORATION: COMPANY OVERVIEW
TABLE 309
TERUMO CORPORATION: PRODUCTS OFFERED
TABLE 310
TERUMO CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026
TABLE 311
TERUMO CORPORATION: DEALS, JANUARY 2023–MARCH 2026
TABLE 312
TERUMO CORPORATION: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 313
FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW
TABLE 314
FRESENIUS SE & CO. KGAA: PRODUCTS OFFERED
TABLE 315
FRESENIUS SE & CO. KGAA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026
TABLE 316
FRESENIUS SE & CO. KGAA: DEALS, JANUARY 2023–MARCH 2026
TABLE 317
FRESENIUS SE & CO. KGAA: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026
TABLE 318
HAEMONETICS CORPORATION: COMPANY OVERVIEW
TABLE 319
HAEMONETICS CORPORATION: PRODUCTS OFFERED
TABLE 320
HAEMONETICS CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026
TABLE 321
HAEMONETICS CORPORATION: DEALS, JANUARY 2023–MARCH 2026
TABLE 322
NIKKISO CO., LTD.: COMPANY OVERVIEW
TABLE 323
NIKKISO CO., LTD.: PRODUCTS OFFERED
TABLE 324
NIKKISO CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026
TABLE 325
SUMITOMO BAKELITE CO., LTD.: COMPANY OVERVIEW
TABLE 326
SUMITOMO BAKELITE CO., LTD.: PRODUCTS OFFERED
TABLE 327
DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 328
DANAHER CORPORATION: PRODUCTS OFFERED
TABLE 329
OTSUKA HOLDINGS CO., LTD.: COMPANY OVERVIEW
TABLE 330
OTSUKA HOLDINGS CO., LTD: PRODUCTS OFFERED
TABLE 331
ASAHI KASEI MEDICAL CO., LTD.: COMPANY OVERVIEW
TABLE 332
ASAHI KASEI MEDICAL CO., LTD.: PRODUCTS OFFERED
TABLE 333
ASAHI KASEI MEDICAL CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026
TABLE 334
MACOPHARMA SA: COMPANY OVERVIEW
TABLE 335
MACOPHARMA SA: PRODUCTS OFFERED
TABLE 336
MEDICA SPA: COMPANY OVERVIEW
TABLE 337
MEDICA SPA: PRODUCTS OFFERED
TABLE 338
POLYMED: COMPANY OVERVIEW
TABLE 339
PURIBLOOD MEDICAL: COMPANY OVERVIEW
TABLE 340
GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
TABLE 341
SAFETRAN BIOMEDICAL INC.: COMPANY OVERVIEW
TABLE 342
MITRA INDUSTRIES PRIVATE LIMITED: COMPANY OVERVIEW
TABLE 343
LONZA: COMPANY OVERVIEW
TABLE 344
LONZA: PRODUCTS OFFERED
TABLE 345
LONZA: DEALS, JANUARY 2023–MARCH 2026
TABLE 346
GRIFOLS: COMPANY OVERVIEW
TABLE 347
GRIFOLS: PRODUCTS OFFERED
TABLE 348
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY OVERVIEW
TABLE 349
CHARLES RIVER LABORATORIES: PRODUCTS OFFERED
TABLE 350
CHARLES RIVER LABORATORIES: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026
TABLE 351
CHARLES RIVER LABORATORIES: DEALS, JANUARY 2023–MARCH 2026
TABLE 352
CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 353
CELLEX CELL PROFESSIONALS: COMPANY OVERVIEW
TABLE 354
CELLEX CELL PROFESSIONALS: PRODUCTS OFFERED
TABLE 355
CELLEX CELL PROFESSIONALS: DEALS, JANUARY 2023–MARCH 2026
TABLE 356
CELLEX CELLS PROFESSIONALS: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 357
STEMCELL TECHNOLOGIES: COMPANY OVERVIEW
TABLE 358
STEMCELL TECHNOLOGIES: PRODUCTS OFFERED
TABLE 359
BIOIVT: COMPANY OVERVIEW
TABLE 360
BIOIVT: PRODUCTS OFFERED
TABLE 361
BIOIVT: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026
TABLE 362
BIOIVT: DEALS, JANUARY 2023–MARCH 2026
TABLE 363
BIOIVT: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 364
DISCOVERY LIFE SCIENCES: COMPANY OVERVIEW
TABLE 365
DISCOVERY LIFE SCIENCES: PRODUCTS OFFERED
TABLE 366
DISCOVERY LIFE SCIENCES: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026
TABLE 367
DISCOVERY LIFE SCIENCES: DEALS, JANUARY 2023–MARCH 2026
TABLE 368
DISCOVERY LIFE SCIENCES: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 369
MILTENYI BIOTEC: COMPANY OVERVIEW
TABLE 370
MILTENYI BIOTEC: PRODUCTS OFFERED
TABLE 371
STEMVIVO INC.: COMPANY OVERVIEW
TABLE 372
STEMVIVO INC.: PRODUCTS OFFERED
TABLE 373
CGT GLOBAL: COMPANY OVERVIEW
TABLE 374
CGT GLOBAL: PRODUCTS OFFERED
TABLE 375
CGT GLOBAL: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026
TABLE 376
SANGUINE BIOSCIENCES: COMPANY OVERVIEW
TABLE 377
SANGUINE BIOSCIENCES: PRODUCTS OFFERED
TABLE 378
SANGUINE BIOSCIENCES: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026
TABLE 379
BIOMEX GMBH: COMPANY OVERVIEW
TABLE 380
ACCEGEN: COMPANY OVERVIEW
TABLE 381
EXCELLOS: COMPANY OVERVIEW
TABLE 382
FIRST CHOICE BIO INC.: COMPANY OVERVIEW
TABLE 383
ORGANA BIO: COMPANY OVERVIEW
TABLE 384
HUMAN CELLS BIO: COMPANY OVERVIEW
TABLE 385
IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS ON LEUKAPHERESIS MARKET
TABLE 386
RISK ASSESSMENT: LEUKAPHERESIS MARKET
FIGURE 1
LEUKAPHERESIS MARKET: SEGMENTATION & REGIONAL SCOPE
FIGURE 2
LEUKAPHERESIS MARKET: YEARS CONSIDERED
FIGURE 4
LEUKAPHERESIS MARKET, 2026–2031
FIGURE 5
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN LEUKOPAKS MARKET, 2024–2026
FIGURE 6
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN LEUKAPHERESIS MARKET, 2024–2026
FIGURE 7
DISRUPTIONS INFLUENCING GROWTH OF LEUKAPHERESIS MARKET
FIGURE 8
HIGH-GROWTH SEGMENTS IN LEUKOPAKS MARKET, 2026–2031
FIGURE 9
HIGH-GROWTH SEGMENTS IN LEUKAPHERESIS MARKET, 2026–2031
FIGURE 10
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN LEUKAPHERESIS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 11
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN LEUKOPAKS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 12
GROWING INCIDENCE OF CANCER TO DRIVE MARKET
FIGURE 13
BLOOD COMPONENT PROVIDERS AND BLOOD CENTERS SEGMENT AND JAPAN ACCOUNTED FOR LARGEST MARKET SHARES IN 2025
FIGURE 14
CHINA TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 15
GROWING PREVALENCE OF LEUKEMIA AND ADOPTION OF CAR T-CELL THERAPY TO DRIVE MARKET
FIGURE 16
MOBILIZED LEUKOPAKS SEGMENT AND CHINA ACCOUNTED FOR LARGEST MARKET SHARES IN 2025
FIGURE 17
CHINA TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 18
LEUKAPHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 19
ESTIMATED NUMBER OF NEW LEUKEMIA CASES, BY REGION (2020 VS. 2040)
FIGURE 20
ESTIMATED NUMBER OF LEUKEMIA DEATHS, BY REGION (2020 VS. 2040)
FIGURE 21
LEUKAPHERESIS MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 22
LEUKAPHERESIS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 23
LEUKAPHERESIS MARKET: VALUE CHAIN ANALYSIS
FIGURE 24
LEUKOPAKS MARKET: VALUE CHAIN ANALYSIS
FIGURE 25
LEUKAPHERESIS MARKET ECOSYSTEM
FIGURE 26
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS IN LEUKAPHERESIS MARKET
FIGURE 27
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES IN LEUKOPAKS MARKET
FIGURE 28
INVESTMENT & FUNDING SCENARIO FOR LEUKAPHERESIS MARKET PLAYERS
FIGURE 29
TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR LEUKAPHERESIS PATENTS (JANUARY 2015–MARCH 2026)
FIGURE 30
LEUKAPHERESIS MARKET: AI USE CASES
FIGURE 31
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LEUKOPAKS
FIGURE 32
KEY BUYING CRITERIA FOR LEUKOPAKS, BY TYPE
FIGURE 33
NORTH AMERICA: LEUKAPHERESIS MARKET SNAPSHOT
FIGURE 34
NORTH AMERICA VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024–2031 (NO. OF BAGS)
FIGURE 35
EUROPE VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024–2031 (NO. OF BAGS)
FIGURE 36
ASIA PACIFIC: LEUKAPHERESIS MARKET SNAPSHOT
FIGURE 37
ASIA PACIFIC VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024–2031 (NO. OF BAGS)
FIGURE 38
LATIN AMERICA VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024–2031 (NO. OF BAGS)
FIGURE 39
MIDDLE EAST & AFRICA VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024–2031 (NO. OF BAGS)
FIGURE 40
REVENUE ANALYSIS OF KEY PLAYERS IN LEUKAPHERESIS MARKET, 2023–2025
FIGURE 41
REVENUE ANALYSIS OF KEY PLAYERS IN LEUKOPAKS MARKET, 2023–2025
FIGURE 42
MARKET SHARE ANALYSIS OF KEY PLAYERS IN LEUKAPHERESIS MARKET, 2025
FIGURE 43
MARKET SHARE ANALYSIS OF KEY PLAYERS IN LEUKOPAKS MARKET, 2025
FIGURE 44
LEUKOPAKS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 45
LEUKOPAKS MARKET: COMPANY FOOTPRINT
FIGURE 46
LEUKOPAKS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 47
EV/EBITDA OF KEY VENDORS FOR LEUKAPHERESIS
FIGURE 48
YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS FOR LEUKAPHERESIS
FIGURE 49
EV/EBITDA OF KEY VENDORS FOR LEUKOPAKS
FIGURE 50
YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS FOR LEUKOPAKS
FIGURE 51
LEUKOPAKS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 52
LEUKAPHERESIS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 53
TERUMO CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 54
FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2025)
FIGURE 55
HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 56
NIKKISO CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 57
SUMITOMO BAKELITE CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 58
DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 59
OTSUKA HOLDINGS CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 60
LONZA: COMPANY SNAPSHOT (2025)
FIGURE 61
GRIFOLS: COMPANY SNAPSHOT (2025)
FIGURE 62
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2025)
FIGURE 63
LEUKAPHERESIS MARKET: RESEARCH DESIGN
FIGURE 64
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS (LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKET)
FIGURE 65
BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKAPHERESIS MARKET)
FIGURE 66
BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER AND REGION (LEUKAPHERESIS MARKET)
FIGURE 67
BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKOPAKS MARKET)
FIGURE 68
BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER AND REGION (LEUKOPAKS MARKET)
FIGURE 69
SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 70
REVENUE SHARE ANALYSIS ILLUSTRATION: TERUMO CORPORATION (2025)
FIGURE 71
DEMAND-SIDE APPROACH: LEUKAPHERESIS MARKET (2025)
FIGURE 72
LEUKAPHERESIS MARKET: CAGR PROJECTIONS (2026–2031)
FIGURE 73
TOP-DOWN APPROACH
FIGURE 74
DATA TRIANGULATION METHODOLOGY
Growth opportunities and latent adjacency in Leukapheresis Market